This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Evaluation of Screening Methods for Treatment of Meibomian Gland Dysfunction

This study has been completed.
Information provided by (Responsible Party):
TearScience, Inc. Identifier:
First received: September 14, 2010
Last updated: November 1, 2011
Last verified: November 2011
The objective is to evaluate the feasibility of using additional screening methods to optimize effectiveness outcomes with the LipiFlow System for application of heat and pressure therapy in adult patients with chronic cystic conditions of the eyelids, including meibomian gland dysfunction, also known as evaporative dry eye or lipid deficiency dry eye, and chalazia. The screening methods include diagnostic expression of the meibomian glands and interferometry assessment of the tear film.

Condition Intervention Phase
Chalazion Dry Eye Syndromes Device: LipiFlow System Phase 2 Phase 3

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Pilot Study for Evaluation of LipiFlow Screening Methods

Further study details as provided by TearScience, Inc.:

Primary Outcome Measures:
  • Association Between Screening Methods (Meibomian Gland Expression) and Treatment Effectiveness Outcomes (Total Meibomian Gland Score) [ Time Frame: Baseline and 4 Weeks ]

    Analysis of association between Baseline Meibomian Gland Expression Score and Total Meibomian Gland Score at 4 Weeks. Success was defined by demonstration of a statistically significant (p<0.05) association between the screening method and outcome.

    Meibomian gland expression sum scores range from 0 to 60 with a higher score reflecting less meibomian gland dysfunction. Total meibomian gland scores range from 0 to 45 with a higher score reflecting less meibomian gland dysfunction.

Enrollment: 50
Study Start Date: September 2010
Study Completion Date: January 2011
Primary Completion Date: January 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: LipiFlow Treatment
Treatment with LipiFlow device
Device: LipiFlow System
In-office treatment for meibomian gland dysfunction


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Meibomian gland dysfunction
  • Dry Eye symptoms

Exclusion Criteria:

  • Ocular surgery, ocular injury or ocular Herpes infection within past 3 months
  • Active ocular infection
  • Active ocular inflammation or recurrent inflammation within past 3 months
  • Moderate to severe allergic conjunctivitis
  • Severe eyelid inflammation
  • Eyelid abnormalities that affect lid function
  • Ocular surface abnormalities that may compromise corneal integrity
  • Systemic disease conditions or medications that cause dry eye
  • Use of other treatments for meibomian gland dysfunction or dry eye
  • Pregnant or nursing women
  • Participation in another ophthalmic clinical trial within past 30 days
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01202747

United States, Illinois
Hoffman Estates, Illinois, United States
United States, Massachusetts
Boston, Massachusetts, United States
Winchester, Massachusetts, United States
Sponsors and Collaborators
TearScience, Inc.
Study Director: Christy Stevens, OD TearScience
  More Information

Responsible Party: TearScience, Inc. Identifier: NCT01202747     History of Changes
Other Study ID Numbers: LF002
Study First Received: September 14, 2010
Results First Received: September 16, 2011
Last Updated: November 1, 2011

Additional relevant MeSH terms:
Dry Eye Syndromes
Keratoconjunctivitis Sicca
Lacrimal Apparatus Diseases
Eye Diseases
Conjunctival Diseases
Corneal Diseases
Eyelid Diseases processed this record on September 21, 2017